Clinical Trial Update: Evaluation of Pirfenidone as a Novel Therapeutic Strategy Against Recurrent Acute Pancreatitis. [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating pirfenidone (Esbriet) as a potential therapy for recurrent acute pancreatitis, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatitis

Drugs mentioned

• Esbriet (pirfenidone)

Snippet

Sponsor: University of Alabama at Birmingham | Conditions: Recurrent Acute Pancreatitis | Phase 2 | Status: RECRUITING